Cargando…

Fixed Monthly versus Less Frequent Ranibizumab Dosing and Predictors of Visual Response in Exudative Age-Related Macular Degeneration

Purpose. To examine temporal patterns of visual acuity (VA) response to pooled 0.3 mg/0.5 mg ranibizumab treatment in patients with age-related macular degeneration and identify potential baseline predictors of response. Design. Retrospective analysis. Methods. Results from 1824 ranibizumab-treated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hariprasad, Seenu M., Morse, Lawrence S., Shapiro, Howard, Wong, Pamela, Tuomi, Lisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3515919/ https://www.ncbi.nlm.nih.gov/pubmed/23251787 http://dx.doi.org/10.1155/2012/690641

Ejemplares similares

Effectiveness of ranibizumab intravitreal injections for exudative age-related macular degeneration treatment: 12-month outcomes
por: Figurska, Małgorzata, et al.
Publicado: (2011)

Ranibizumab plus fufang xueshuantong capsule versus ranibizumab alone for exudative age-related macular degeneration
por: Pan, Hai-Tao, et al.
Publicado: (2020)

Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab
por: Hamid, Mohamed A., et al.
Publicado: (2021)

Clinically meaningful visual improvements and predictors of early vision gains with ranibizumab for diabetic macular oedema
por: Morse, Lawrence, et al.
Publicado: (2019)

The effect of ranibizumab versus photodynamic therapy on DNA damage in patients with exudative macular degeneration
por: Mozaffarieh, M, et al.
Publicado: (2009)

Visual outcome of intravitreal ranibizumab for exudative age-related macular degeneration: timing and prognosis
por: Canan, Handan, et al.
Publicado: (2014)

Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration
por: Barthelmes, Daniel, et al.
Publicado: (2016)

Results of switchback from ranibizumab to aflibercept in patients with exudative age-related macular degeneration
por: Koike, Naoko, et al.
Publicado: (2019)

Comparing the Effectiveness of Bevacizumab to Ranibizumab in Patients with Exudative Age-Related Macular Degeneration. The BRAMD Study
por: Schauwvlieghe, A. M. E., et al.
Publicado: (2016)

The Effect of Ranibizumab on Normal Neurosensory Retina in the Eyes of Patients with Exudative Age Related Macular Degeneration
por: Makri, Olga E., et al.
Publicado: (2017)

The effect of vitreomacular adhesion in exudative age-related macular degeneration on the results of ranibizumab intravitreal injection
por: Suzuki, Hiroyuki, et al.
Publicado: (2017)

Comparison of the effect between pegaptanib and ranibizumab on exudative age-related macular degeneration with small lesion size
por: Nishimura, Yoshihiro, et al.
Publicado: (2012)

One-Year Results of Photodynamic Therapy Combined with Intravitreal Ranibizumab for Exudative Age-Related Macular Degeneration
por: Nakamura, Tomoko, et al.
Publicado: (2012)

Effect of ranibizumab on serous and vascular pigment epithelial detachments associated with exudative age-related macular degeneration
por: Panos, Georgios D, et al.
Publicado: (2013)

AFLIBERCEPT AFTER RANIBIZUMAB INTRAVITREAL INJECTIONS IN EXUDATIVE AGE–RELATED MACULAR DEGENERATION: The ARI2 Study
por: Blanco-Garavito, Rocio, et al.
Publicado: (2018)

Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab and/or Ranibizumab for Neovascular Age-Related Macular Degeneration
por: Griffin, David R., et al.
Publicado: (2014)

Intravitreal aflibercept treatment in eyes with exudative age-related macular degeneration following prior treatment with intravitreal ranibizumab
por: Narayan, Daniel Sanju, et al.
Publicado: (2015)

Ganglion Cell Complex Evaluation in Exudative Age-Related Macular Degeneration after Repeated Intravitreal Injections of Ranibizumab
por: Perdicchi, Andrea, et al.
Publicado: (2015)

Role of ranibizumab in management of macular degeneration
por: Singh, Rishi P, et al.
Publicado: (2007)

Two-year outcomes of pro re nata ranibizumab monotherapy for exudative age-related macular degeneration in Japanese patients
por: Yamamoto, Akiko, et al.
Publicado: (2013)

Ranibizumab in neovascular age-related macular degeneration
por: Eng, Kenneth T, et al.
Publicado: (2006)

FUSION regimen: ranibizumab in treatment-naïve patients with exudative age-related macular degeneration and relatively good baseline visual acuity
por: Monés, Jordi, et al.
Publicado: (2012)

Lucentis(®) using Visudyne(®) study: determining the threshold-dose fluence of verteporfin photodynamic therapy combined with intravitreal ranibizumab for exudative macular degeneration
por: Chen, Eric, et al.
Publicado: (2010)

Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial)
por: Wykoff, Charles C, et al.
Publicado: (2014)

Treatment of age-related macular degeneration: focus on ranibizumab
por: Spitzer, Martin S, et al.
Publicado: (2008)

Current Smoking Is Associated with a Poor Visual Acuity Improvement after Intravitreal Ranibizumab Therapy in Patients with Exudative Age-Related Macular Degeneration
por: Lee, Sangmoon, et al.
Publicado: (2013)

Therapeutic Modalities of Exudative Age-related Macular Degeneration
por: Mavija, Milka, et al.
Publicado: (2014)

Brolucizumab for persistent macular fluid in neovascular age-related macular degeneration after prior anti-VEGF treatments
por: Hussain, Rehan M., et al.
Publicado: (2021)

Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration
por: Hurley, Susan F, et al.
Publicado: (2008)

Individualized Therapy with Ranibizumab in Wet Age-Related Macular Degeneration
por: García-Layana, Alfredo, et al.
Publicado: (2015)

Real-World Results of Aflibercept versus Ranibizumab for the Treatment of Exudative AMD Using a Fixed Regimen
por: Providência, Joana, et al.
Publicado: (2018)

Foveal Exudative Macroaneurysm Treated with Intravitreal Ranibizumab
por: Menezes, Carlos, et al.
Publicado: (2015)

Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema
por: Fong, Angie HC, et al.
Publicado: (2013)

Macular morphology and response to ranibizumab treatment in patients with wet age-related macular degeneration
por: Dervenis, Nikolaos, et al.
Publicado: (2016)

One-year outcomes of fixed treatment of intravitreal aflibercept for exudative age-related macular degeneration and the factor of visual prognosis
por: Ono, Aoi, et al.
Publicado: (2018)

Safety and tolerability of ranibizumab in uni/bilateral neovascular age-related macular degeneration: 12-month TWEYEs study
por: Bandello, Francesco, et al.
Publicado: (2020)

Early Signs of Exudative Age-Related Macular Degeneration in Asians
por: Sasaki, Mariko, et al.
Publicado: (2014)

Treatment of Exudative Age-related Macular Degeneration: Focus on Aflibercept
por: García-Layana, Alfredo, et al.
Publicado: (2015)

Unusual visual loss in a patient with exudative macular degeneration
por: Peng, Enoch T., et al.
Publicado: (2022)

Association of Metformin and Other Diabetes Medication Use and the Development of New-Onset Dry Age-Related Macular Degeneration: A Case–Control Study
por: Kaufmann, Gabriel T., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_t9apshhnv0rspelagobpge0gpm